Pharming PHAR Stock
Pharming Price Chart
Pharming PHAR Financial and Trading Overview
| Pharming stock price | 9.05 USD |
| Previous Close | 12.04 USD |
| Open | 12.1 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 800 |
| Day's Range | 12.1 - 12.56 USD |
| 52 Week Range | 6.71 - 17.81 USD |
| Volume | 653 USD |
| Avg. Volume | 24.55K USD |
| Market Cap | 807.96M USD |
| Beta (5Y Monthly) | 0.878544 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PHAR Valuation Measures
| Enterprise Value | 763.72M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.008834 |
| Price/Book (mrq) | 3.970968 |
| Enterprise Value/Revenue | 3.789 |
| Enterprise Value/EBITDA | -818.569 |
Trading Information
Pharming Stock Price History
| Beta (5Y Monthly) | 0.878544 |
| 52-Week Change | 69.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.81 USD |
| 52 Week Low | 6.71 USD |
| 50-Day Moving Average | 11.68 USD |
| 200-Day Moving Average | 11.75 USD |
PHAR Share Statistics
| Avg. Volume (3 month) | 24.55K USD |
| Avg. Daily Volume (10-Days) | 2.46K USD |
| Shares Outstanding | 65.63M |
| Float | 59.97M |
| Short Ratio | 0.73 |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.048% |
| Shares Short | 2.75K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -0.99% |
| Operating Margin (ttm) | -3.036% |
| Gross Margin | 91.68% |
| EBITDA Margin | -0.46% |
Management Effectiveness
| Return on Assets (ttm) | -0.93% |
| Return on Equity (ttm) | -1.014% |
Income Statement
| Revenue (ttm) | 201.55M USD |
| Revenue Per Share (ttm) | 3.17 USD |
| Quarterly Revenue Growth (yoy) | -8.69% |
| Gross Profit (ttm) | 188.06M USD |
| EBITDA | -933000 USD |
| Net Income Avi to Common (ttm) | -1995000 USD |
| Diluted EPS (ttm) | -0.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 184.78M USD |
| Total Cash Per Share (mrq) | 2.88 USD |
| Total Debt (mrq) | 170.4M USD |
| Total Debt/Equity (mrq) | 85.48 USD |
| Current Ratio (mrq) | 4.509 |
| Book Value Per Share (mrq) | 3.1 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -936000 USD |
| Levered Free Cash Flow (ttm) | -1643375 USD |
Profile of Pharming
| Country | United States |
| State | N/A |
| City | Leiden |
| Address | Darwinweg 24 |
| ZIP | 2333 CR |
| Phone | 31 71 524 7400 |
| Website | https://www.pharming.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 332 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Q&A For Pharming Stock
What is a current PHAR stock price?
Pharming PHAR stock price today per share is 9.05 USD.
How to purchase Pharming stock?
You can buy PHAR shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pharming?
The stock symbol or ticker of Pharming is PHAR.
Which industry does the Pharming company belong to?
The Pharming industry is Biotechnology.
How many shares does Pharming have in circulation?
The max supply of Pharming shares is 67.34M.
What is Pharming Price to Earnings Ratio (PE Ratio)?
Pharming PE Ratio is now.
What was Pharming earnings per share over the trailing 12 months (TTM)?
Pharming EPS is -0.16 USD over the trailing 12 months.
Which sector does the Pharming company belong to?
The Pharming sector is Healthcare.
Pharming PHAR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17019.88 USD — |
+0.59
|
5.94B USD — | 16917.51 USD — | 17032.66 USD — | — - | 5.94B USD — |
| NASDAQ Global Market Composite NQGM | 2247.92 USD — |
-0.06
|
— — | 2233.52 USD — | 2269.56 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 978.74 USD — |
-1.03
|
— — | 973.64 USD — | 990.74 USD — | — - | — — |
- {{ link.label }} {{link}}